checkAd

    EQS-News  201  0 Kommentare Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

    Für Sie zusammengefasst
    • Mainz Biomed presents new data at ASCO 2024
    • Key findings: 92.3% sensitivity for CRC
    • Largest study to date with 690 subjects

    Issuer: Mainz BioMed N.V. / Key word(s): Conference
    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

    28.05.2024 / 14:01 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

    Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions

    Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm

    BERKELEY, US – MAINZ, Germany – May 28th, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. This prestigious conference will be held from May 31 to June 4, 2024, in Chicago, Illinois, and online, serving as a leading forum for the latest developments in oncology.

    The combined analysis from the ColoFuture and eAArly DETECT studies represents the largest dataset to date, with 690 subjects including previously unexamined and unreported subjects enrolled across 30 clinical sites. These studies were designed to assess the performance of a novel stool-based approach that combines mRNA signatures and the Fecal Immunochemical Test (FIT) with an AI-generated algorithm to improve diagnostic performance for detecting colorectal cancer and advanced precancerous lesions.

    Presentation Details

    Title: “A Novel, Non-Invasive, Multimodal Screening Test for Early Detection of Precancerous Lesions and Colorectal Cancer Using an Artificial Intelligence-Based Algorithm.”

    Presenter: Dr. D. Kim Turgeon
    Session: Saturday, June 1, 2024, from 13:30 to 16:30 CDT
    Abstract #: 3627
    Poster Bd#: #290
    Citation: J Clin Oncol 42, 2024 (suppl 16; abstr 3627)

    This multimodal screening test shows a significant improvement over existing non-invasive methods, particularly in detecting advanced precancerous lesions (APLs) such as advanced adenomas, which are critical for early intervention. By leveraging this approach, Mainz Biomed aims to revolutionize colorectal cancer screening practices and contribute to a reduction in cancer mortality rates worldwide.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting Issuer: Mainz BioMed N.V. / Key word(s): Conference Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting 28.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the …

    Schreibe Deinen Kommentar

    Disclaimer